



Journal of Clinical Epidemiology

Journal of Clinical Epidemiology 127 (2020) 202-207

COVID-19 SERIES

Using GRADE in situations of emergencies and urgencies: certainty in evidence and recommendations matters during the COVID-19 pandemic, now more than ever and no matter what

Holger J. Schünemann^{a,b,*}, Nancy Santesso^a, Gunn E. Vist^c, Carlos Cuello^a, Tamara Lotfi^a, Signe Flottorp^c, Marina Davoli^d, Reem Mustafa^e, Joerg J. Meerpohl^f, Pablo Alonso-Coello^g, Elie A. Akl^h

^aDepartment of Health Research Methods, Evidence, and Impact, World Health Organization Collaborating Center for Infectious Diseases, Research Methods and Recommendations, Michael G. DeGroote Cochrane Canada & McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada

^bDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada

^cDivision for Health Services, Norwegian Institute of Public Health, Oslo, Norway

^dDepartment of Epidemiology Lazio Region, Via Cristoforo Colombo 112, Rome, Italy

^eDepartment of Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA

finstitute for Evidence in Medicine, Medical Center and Faculty of Medicine & Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany Biberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau-CIBERESP), Barcelona 08025, Spain hAmerican University of Beirut Medical Center, P.O.Box 11-0236 / CRI (E15), Riad-El-Solh, Beirut 1107 2020, Lebanon

Accepted 31 May 2020; Published online 6 June 2020

Abstract

Objectives: The public, policy makers, and science communities are subject to many false, uninformed, overly optimistic, premature, or simply ridiculous health claims. The coronavirus disease 2019 (COVID-19) pandemic and its context is a paramount example for such claims. In this article, we describe why expressing the certainty in evidence to support a decision is critical and why the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach matters now, perhaps more than ever and no matter what the specific topic is in relation to COVID-19. We finally also offer suggestions for how it can be used appropriately to support decision-making at global, national, and local level when emergency, urgent or rapid responses are needed.

Study Design and Setting: This is an invited commentary to address the objectives above building on examples from the recent COV-ID-19 pandemic. This includes an iterative discussion of examples and development of guidance.

Results: The GRADE approach is a transparent and structured method for assessing the certainty of evidence and when developing recommendations that requires little additional time. We describe why emergency, urgent, or rapid responses do not justify omitting this critical assessment of the evidence. In situations of emergencies and urgencies, such as the COVID-19 pandemic, GRADE can similarly be used to express and convey certainty in intervention effects, test accuracy, risk and prognostic factors, consequences of public health measures, and qualitative bodies of evidence.

Conclusions: Assessing and communicating the certainty of evidence during the COVID-19 pandemic is critical. Those offering evidence synthesis or making recommendations should use transparent ratings of the body of evidence supporting a claim regardless of time that is available or needed to provide this response. © 2020 Elsevier Inc. All rights reserved.

Keyworks: GRADE; Pandemics; Systematic reviews; Recommendations; Guidelines

E-mail address: schuneh@mcmaster.ca (H.J. Schünemann).

Conflict of interest: H.J.S. is the cochair of the GRADE working group. N.S., E.A., P.A.-C., C.C., G.V., M.D., R.M., J.M., and S.F. are members of the GRADE working group. However, this article does not necessarily represent official views of the GRADE working group and is an invited commentary.

^{*} Corresponding author. Michael G. DeGroote Cochrane Canada and McGRADE Centres, Departments of Health Research Methods, Evidence and Impact and of Medicine McMaster University Health Sciences Centre, Room 2C16 1280 Main Street West Hamilton, ON L8S 4K1, Canada, Tel: +1 905 525 9140 x 24931.

Box 1 GRADE questions to ask about the certainty in the body of evidence per outcome:

- Are the study designs used appropriate?
- Are there important limitations in the research design or execution of the research?
- Are the results consistent across studies when the settings, populations, interventions, comparators, and outcomes are reasonably similar?
- How directly do the results apply to the population (including setting), intervention, comparator, and outcomes (PICO) of interest?
- Are the results precise enough or likely due to chance?
- Is this all the research that has been conducted on the PICO question of interest?
- Is there anything, in particular very large effects of an intervention, dose response gradients, or unfavorable scenarios still leading to convincing effects, that makes us more confident?

1. Background

The public, policy makers, and science communities are subject to many false, uninformed, overly optimistic, premature, or simply ridiculous health claims. The coronavirus disease 2019 (COVID-19) pandemic and its context is a paramount example for such claims: from media and politician's attention to biased interpretation of case series of patients on hydroxychloroquine to the injection of disinfectants and use of azithromycin [1]. Yet, for some interventions, such as personal protective equipment (PPE) and social distancing, there is an accumulating body of evidence in favor of their benefits [2]. To monitor misleading and appropriate claims and separate biased from unbiased research, understanding and expressing the certainty in effects of these and other clinical, public health, or health policy interventions is critical to weed out misleading or wrongful claims. It is more critical than in other situations because policy makers are under unprecedented pressure to react to claims and make decisions with varying degrees of certainty in the evidence and timing of their responses. And it is especially critical in this era because of the public access to information and expectation of a timely response.

The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach provides a transparent and structured approach to making judgments about the certainty of the evidence, and offers a transparent process to making recommendations and decisions [3–6]. GRADE is the product of an open and inclusive community of people that has collaborated for 20 years (www.gradeworkinggroup.org) and is currently used by over 100 organizations globally, including the World Health

Box 2 GRADE questions when recommending for or against an intervention or strategy

- Are the expected health benefits greater than the harms or vice versa (this integrates considerations about the priority and severity of the problem, intervention effects, the values people place on the outcomes, as well as the certainty in the effects)?
- What is the magnitude of the resource requirements (and associated cost) related to the intervention/ strategy and is it cost-effective?
- What is the impact of the intervention/strategy on equity, including societal implications and environmental impact?
- Is the intervention/strategy acceptable to different stakeholders (this criterion includes ethical and other considerations)?
- Is the intervention/strategy feasible (this criterion includes health system, social, legal, political, and other considerations)?

Organization (WHO). The GRADE working group has used a carefully designed, rigorous, transparent, and inclusive process based on cumulative evidence about research methods, bias, and decision-making. GRADE offers solutions to the dilemma of expressing certainty in a body of evidence, which would have been very low certainty in efficacy of hydroxychloroquine because of imprecision and the nonrandomized designs used [7], and at least moderate certainty in physical distancing based on other indirect evidence from viral respiratory diseases research [2]. GRADE also offers a structured and transparent framework for making decisions, including recommendations, that should prove particularly helpful during the ongoing COVID-19 pandemic. In this article, after having made the point why we think expressing certainty in evidence to support a decision is critical above, we describe why GRADE matters now, perhaps more than ever and no matter what the specific topic is in relation to COVID-19. We finally also offer suggestions for how it can be used appropriately to support decision-making at global, national, and local level.

2. How to use GRADE in the COVID-19 era

Decision makers should, and many are (!), asking "what is the science?" and "how good is this test or this intervention?". GRADE, although appropriately sophisticated in its full execution, can answer these questions and be relayed to decision makers by breaking its components down into straightforward questions about 1) the certainty of evidence and 2) the criteria for making decisions or recommendations. While ideally applied to rate the certainty of a body




Fig. 1. The use of GRADE to assess the certainty in: (1) emergency responses or in an ultra-short time frame of hours; (2) urgent responses, allowing one to two weeks to respond; (3) rapid responses, in up to three months; and (4) routine responses, beyond three months.

of evidence in a well-conducted and up-to-date evidence synthesis relevant to the question at hand (in terms of setting, population, intervention, comparator, and outcomes) with corresponding summary tables, such as evidence profiles; GRADE's application requires at least that "the evidence that was assessed and the methods that were used to identify and appraise that evidence should be clearly described" [4,8–10].

Those providing and using evidence should ask the questions in box 1 to understand if they can be certain about the effects of an intervention (including tests, public health strategies or other options being considered), regardless of the time available. Based on the answers to these questions, an expression of certainty in the body of evidence can be articulated (GRADE uses four levels of certainty: high, moderate, low, and very low) [4].

The questions proposed by GRADE to guide decision makers, including those formulating recommendations (and the recipients of them), are equally simple (Box 2), and can be tailored to the type of decision (clinical recommendations, public health recommendations/decisions, or health system recommendations/decisions) [11,12].

2.1. Emergency, urgent, rapid, and routine use of GRADE to assess the certainty of evidence

Early in the COVID-19 pandemic, it became evident that information is required with different levels of urgency. We

previously described these different levels of time-based responses using GRADE (Figure 1), and categorized the use of GRADE to assess the certainty in 1) emergency responses or in an ultrashort time frame of hours; 2) urgent responses, allowing one to 2 weeks to respond; 3) rapid responses, in up to 3 months; and 4) routine responses, beyond 3 months [10].

An example of the first scenario, that is, providing GRADEd evidence within hours, is when it became apparent that a viral outbreak was the likely cause of what is now known as COVID-19. Under those circumstances, addressing the value of use of masks as PPE or distancing within hours became an emergency question to be answered. Indeed, indirect evidence from other viral outbreaks could have been used within hours. Credible systematic reviews of related conditions available at the time of the outbreak provide evidence about what measures to take. However, one would need to lower the original rating of certainty of the evidence to account for the indirectness of the population that was likely affected by an unknown virus [13]. This is because the answer to the question "How directly do the results of the research apply to the population and situation of my interest?" would have been that we know from other viral diseases that PPE has an effect but we cannot be as certain that it will be similar in this new outbreak. That an influenza virus or coronavirus were likely pathogens would have been supported by the type of clinical and public health presentation, and prior history of

outbreaks caused by these viruses. Given the unknown exact virus, however, whether the effect of use of masks for COVID-19 is larger or smaller would have be unknown, as masks may be more or less effective depending on the exact mode of transmission of the virus as well as other factors. An informative narrative synthesis based on GRADE guidance for the state of the evidence about masks would have been "the use of masks may reduce the risk of transmission of respiratory virus (low certainty in the evidence due to indirectness based on seven case-control studies showing large effects of severe acute respiratory syndrome from coronavirus transmission) [13,14]. Similarly, one would have high certainty that a large distance from the source is effective, yet the certainty in how much distance to keep, for example, 1 m or 2 m or more, would be rated down for that same indirectness.

For the second scenario of using GRADE with urgency (one to 2 weeks), the COVID-19 pandemic has made it clear that systematic reviews can be conducted to respond to urgencies (defined as responding within 2 weeks) without "cutting corners", for which rapid reviews have been criticized [15,16]. To illustrate this point, we present three standard urgent systematic reviews that we have conducted within 7 to 11 days each, two of them in parallel and one including many complex meta-analyses, including Bayesian approaches and a meta-regression. The three reviews addressed five questions on the use of masks, eye protection, and physical distancing; use of noninvasive ventilation; and handling of bodies of deceased individuals [2,17-19]. We produced five GRADE evidence profiles with a rating of the certainty after reviewing over 80,000 citations, and including over 70 studies. The review on the use of masks and physical distancing featured studies directly addressing COVID-19 and provides low to moderate certainty about large effects, and high certainty for any observed reduction in transmission by physical distancing although the exact effect is only of moderate certainty. Thus, for a situation of urgency and beyond, GRADE assessments based on systematic reviews are possible, albeit in the hands of a large experienced systematic review team. Contrary to what some believe, however, applying GRADE does not add significant time to the systematic review process. The time required to produce evidence profiles and add appropriate ratings of the certainty was approximately 1 hour. We believe the investment of time has paid off. In the earlier phases of the review, we saved time through streamlining the evidence assessments, structuring the questions and making decisions about what evidence to search for to address relevant outcomes as suggested by GRADE [9]. For example, to address the risk of COVID-19 transmission, we realized that studies addressing this risk during aerosolizing procedures such as noninvasive ventilation required a search for a different type of evidence, including mechanical and laboratory studies. While we conducted meta-analyses for many of our outcomes, something that it is often not possible, GRADE can be

applied to narrative summaries of the evidence, and still provide guidance with informative statements about the findings [10,20].

For the third scenario of using GRADE within 3 months, we previously described the use of GRADE using a framework for developing rapid recommendations, that is, in up to 3 months [21]. In 2007, an expert committee at the WHO developed 23 separate recommendations, and a number of research recommendations for or against the pharmacological treatment of avian influenza [22]. Avian influenza was a serious public health threat of a pandemic at that time that, however, did not emerge, leaving more time to act compared with COVID-19 [22]. In addition to reviewing human studies, it included a review of mechanistic and animal research evidence. For COVID-19 addressing, the question about hydroxychloroquine, remdesivir, antibody testing, and other pharmacological interventions, rapid reviews (and subsequent monitoring) allow accumulation of evidence emerging during an outbreak for treatment, interventions, or strategies that may or may not be providing net benefit [23]. The accumulating evidence about mask use and physical distancing demands transitioning from urgent answers to rapid and routine answers, where new evidence is integrated, perhaps in living reviews, to provide best evidence for longer-term decisions [18,24].

Indeed, there will be answers to COVID-19-related questions that may need, perhaps after provisional urgent evidence assessments, routine monitoring using GRADE beyond 3 months. This may include addressing rehabilitation needs for patients suffering respiratory or neurological consequences or the impact of telemedicine on patient outcomes and health care utilization after COVID-19 infection. In a partnership with the Norwegian Institute of (https://www.fhi.no/en/qk/ Public Health (NIPH) systematic-reviews-hta/map/) and authors' institutions, we are making risk of bias assessments of individual studies and ratings of the certainty of a body of evidence for questions related to COVID-19 increasingly available which can be used globally by the evidence synthesis community, including Cochrane rapid COVID-19 reviews [25]. One of the goals is avoidance of duplication.

3. GRADE for COVID-19 and other recommendations

Using our rationale aforementioned, to optimally inform the public, it is inappropriate for politicians and organizations to not transparently convey the certainty narratively or provide ratings of it.

Policies have to be made regardless of the type of evidence that exists, even if there is low or very low certainty in the exact effect of an intervention or strategy, such as for the urgent answer about masks for the public. Those using GRADE are then often asked if policy makers do not shy away from making recommendations based on low or very low certainty evidence, and if they will be hesitant to

communicate uncertainty of the evidence to the public. An adequate response is that evidence and studies are never perfect, and that there is always uncertainty but even in a new outbreak one can build on indirect evidence. An interpretation for policy makers of an effect labeled with low certainty would be: Although our confidence in the effect estimate is (still) low, a harm (transmission) reduction is likely assumed on the basis of the current best evidence. More research will likely increase our certainty in the effect. But, if all other factors necessary for a decision (Box 2) are considered (of which the effect is the most important but not the only one), it should be possible to reach a decision that is transparent. Decision makers are making complex decisions that balance the value placed on public health consequences, resources, equity, and feasibility. Using the structured GRADE framework, for example, for a recommendation against masks, it would be clear that it is not based on what we know about the effect, but on other factors such as equity, resource use, or feasibility.

To develop guidance, tools exist [26,27], and if used appropriately in the context of GRADE, we can inform decision makers appropriately and convey our certainty in any recommendation that evolves, on an emergency basis or over longer periods. When a structured and transparent approach is used, it facilitates the sharing of information and an understanding of the basis of decisions. To complement the Norwegian Institute of Public Health's evidence map of available COVID-19 evidence, we have partnered with NIPH and other groups, some represented by the authors of this article, to populate a recommendation catalog and map for COVID-19 that includes trustworthy recommendations and information to make decisions (https:// covid19.evidenceprime.com/), both directly and contextualized to different settings, using the GRADE Adolopment methodology [28,29]. As with the evidence map, also here the goal is to avoid duplication, build on each other's work given the many guidance documents that are produced already, and make it available to platforms that link to recommendations such as the Guidelines International Network COVID-19 website and other initiatives [30,31].

4. Conclusion

Assessing and communicating the certainty of evidence during the COVID-19 pandemic is critical. Emergency, urgent, or rapid responses do not justify omitting this critical assessment of the evidence. Those offering evidence synthesis or making recommendations should use transparent ratings of the body of evidence supporting a claim. Although we focused on intervention effects, GRADE can be used to assess and communicate the certainty of evidence from models, prognostic studies, patient's values, tests, and preclinical animal research [32–35]. There are good reasons to provide such certainty ratings and GRADE

as the most disseminated and accepted approach globally has and can be used in the ongoing COVID-19 pandemic [2,18,19,36,37].

CRediT authorship contribution statement

Holger J. Schünemann: Conceptualization, Writing - original draft. Nancy Santesso: Writing - review & editing. Gunn E. Vist: Writing - review & editing. Carlos Cuello: Writing - review & editing. Tamara Lotfi: Writing - review & editing. Signe Flottorp: Writing - review & editing. Marina Davoli: Writing - review & editing. Reem Mustafa: Writing - review & editing. Joerg J. Meerpohl: Writing - review & editing. Pablo Alonso-Coello: Writing - review & editing. Elie A. Akl: Writing - review & editing.

Acknowledgments

This article does not necessarily represent official views of the GRADE working group but describes the application of GRADE.

Authors' contributions: H.J.S. contributed to conceptualization and roles/writing—original draft; N.S., E.A., P.A.-C., C.C., G.V., M.D., R.M., J.M., and S.F. contributed to writing—review and editing.

References

- [1] Gautret P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Inter J Antimicrob Agents 2020;56(1):105949.
- [2] Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schunemann HJ, et al. COVID-19-SURGE Authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet 2020;395:1973—87.
- [3] Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
- [4] Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383—94.
- [5] Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336: 924-6.
- [6] Schunemann HJ, Best D, Vist G, Oxman AD, Group GW. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ 2003;169:677–80.
- [7] Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis. J Med Virol 2020;92(7):776–85.
- [8] GRADE_Working_Group. Available at https://www.gradeworking group.org/docs/Criteria_for_using_GRADE_2016-04-05.pdf. Accessed March 12, 2016.
- [9] Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol 2013;66:173–83.

- [10] Thayer KA, Schunemann HJ. Using GRADE to respond to health questions with different levels of urgency. Environ Int 2016;92-93: 585-9
- [11] Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ 2016;353: i2016.
- [12] Moberg J, Oxman AD, Rosenbaum S, Schunemann HJ, Guyatt G, Flottorp S, et al. The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Health Res Policy Syst 2018;16:45.
- [13] Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 2011CD006207.
- [14] Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol 2020;119:126–35.
- [15] Dahm P, Kunz R, Schunemann H. Evidence-based clinical practice guidelines for prostate cancer: the need for a unified approach. Curr Opin Urol 2007;17:200-7.
- [16] Featherstone RM, Dryden DM, Foisy M, Guise JM, Mitchell MD, Paynter RA, et al. Advancing knowledge of rapid reviews: an analysis of results, conclusions and recommendations from published review articles examining rapid reviews. Syst Rev 2015;4:50.
- [17] Schunemann HJ, Moja L. Reviews: rapid! Rapid! Rapid! ...and systematic. Syst Rev 2015;4:4.
- [18] Schunemann HJ, Khabsa J, Solo K, Khamis AM, Brignardello-Petersen R, El-Harakeh A, et al. Ventilation techniques and Risk of Transmission for coronavirus disease including Covid-19: a living systematic review of multiple streams of evidence. Ann Intern Med 2020;173:204—16.
- [19] Yaacoub S, Schünemann HJ, Khabsa J, El-Harakeh A, Khamis AM, Chamseddine F, et al. Safe management of bodies of deceased persons with suspected or confirmed COVID-19: a rapid systematic review. BMJ Glob Health 2020;5(5):e002650.
- [20] Murad MH, Mustafa RA, Schunemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med 2017;22:85-7.
- [21] Schunemann HJ, Hill SR, Kakad M, Vist GE, Bellamy R, Stockman L, et al. Transparent development of the WHO rapid advice guidelines. PLoS Med 2007;4:e119.
- [22] Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007;7:21-31.

- [23] https://covid-nma.com Protocol can be found here: https://zenodo. org/record/3744600#.Xp6X_i17H6x. Accessed May 24, 2020.
- [24] De Crescenzo FAL, Vecchi S, D'Alo' GL, Cruciani F, Mitrova Z, Saulle R, et al. Comparative effectiveness of pharmacological interventions for Covid-19: a living systematic review and network meta-analysis. Syst Rev 2020;9:1.
- [25] Cochrane. Cochrane COVID Rapid Reviews website and Question Bank. Accessed May 24, 2020.
- [26] Morgan RL, Florez I, Falavigna M, Kowalski S, Akl EA, Thayer KA, et al. Development of rapid guidelines: 3. GIN-McMaster Guideline Development Checklist extension for rapid recommendations. Health Res Policy Syst 2018;16:63.
- [27] Kowalski SC, Morgan RL, Falavigna M, Florez ID, Etxeandia-Ikobaltzeta I, Wiercioch W, et al. Development of rapid guidelines: 1. Systematic survey of current practices and methods. Health Res Policy Syst 2018;16:61.
- [28] Schunemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: grade-adolopment. J Clin Epidemiol 2017;81:101-10.
- [29] Tugwell P, Knottnerus JA. Adolopment a new term added to the clinical epidemiology lexicon. J Clin Epidemiol 2017;81:1-2.
- [30] COVID-END. COVID-END 2020. Accessed May 24, 2020.
- [31] Network GI.
- [32] Hooijmans CR, de Vries RBM, Ritskes-Hoitinga M, Rovers MM, Leeflang MM, IntHout J, et al. Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies. PLoS One 2018;13:e0187271.
- [33] Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ 2015;350:h870.
- [34] Spencer FA, Iorio A, You J, Murad MH, Schunemann HJ, Vandvik PO, et al. Uncertainties in baseline risk estimates and confidence in treatment effects. BMJ 2012;345:e7401.
- [35] Zhang Y, Alonso-Coello P, Guyatt GH, Yepes-Nunez JJ, Akl EA, Hazlewood G, et al. GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences-Risk of bias and indirectness. J Clin Epidemiol 2019;111:94–104.
- [36] Bhimraj A, Morgan RL, Hirsch Shumaker A, Lavergne V. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 2020.
- [37] Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med 2020;48(6):e440–69.